HCU Updates

Experiences of diagnosis and patient satisfaction

A paper from the HCU Network Australia survey on the experiences of the homocystinuri…

more

Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

Aeglea BioTherapeutics, Inc.has announced the U.S. Food and Drug Administration (FDA)…

more

Events

30th November 2021

more

Videos

View HCU YouTube Channel

Sponsors & Partners